Ann: Regulatory Approval for Remplir Nerve Repair Device, page-62

Oh I think nearly everyone but management agree that OCC has these excellent products, but are failing to get them to market quickly enough, through slow/inadequate trialing and commercialisation - their listing history since 2014 has been full over promise and pushed back timelines. I don't think there is an investor on HC who would disagree that. Its undeniable. I personally would have rather they gone the less lucrative 510K route for Remplir with the FDA - we'd be approved and possibly even taking US revenue already, but hey ho.

They have at least finally kicked regulatory approval goals in 2021/2.

For other investors, go back a page and at the end I did provide a good bit of US market analysis / studies for CelGro Nerve (Remplir) and the potential numbers of applications (20 million Americans with perhipheral nerve damage, low initial trauma diagnosis, etc). Similarly that suggests more potential surgical applications that the 12,000 offered by OCC in simple yearly preipheral nerve operation stats.